TO901317 inhibits the development of hepatocellular carcinoma by LXRalpha/Glutl decreasing glycometabolism

摘要

This study was conducted to observe the effect and possible mechanism of TO901317 in vivo and in vitro to provide a new basis for the targeted therapy of hepatocellular carcinoma (HCC). The expressions of liver X receptor (LXR)-a, glucose transporter (Glut)-l, proliferating cell nuclear antigen (PCNA), and matrix melalloproteinase (MMP)-9 were analyzed from HCC public database (NCBI PubMed database).